Zealand Pharma A/S (CPH:ZEAL)
Denmark
· Delayed Price · Currency is DKK 234.90
-134.30 (-36.38%)
At close: Mar 6, 2026
Zealand Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 9,215 | 62.69 | 342.79 | 103.99 | 108.55 | Upgrade
|
| Revenue Growth (YoY) | 14598.86% | -81.71% | 229.65% | -4.20% | -43.47% | Upgrade
|
| Cost of Revenue | 0.82 | 7.87 | 3.2 | - | 10.97 | Upgrade
|
| Gross Profit | 9,214 | 54.82 | 339.59 | 103.99 | 97.58 | Upgrade
|
| Selling, General & Admin | 495.95 | 404.02 | 215.93 | 269.51 | 298.21 | Upgrade
|
| Research & Development | 1,605 | 919.87 | 684.9 | 614.04 | 581.51 | Upgrade
|
| Other Operating Expenses | 196.42 | - | - | 48.27 | - | Upgrade
|
| Operating Expenses | 2,297 | 1,324 | 900.83 | 920.59 | 879.72 | Upgrade
|
| Operating Income | 6,917 | -1,269 | -561.24 | -816.6 | -782.14 | Upgrade
|
| Interest Expense | -29.06 | -34.05 | -25.83 | -57.79 | -4.09 | Upgrade
|
| Interest & Investment Income | 309.34 | 169.64 | 45.32 | 6.54 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -295.1 | 18.29 | -9.71 | 25.6 | 36.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.73 | -17.46 | -1.99 | 11.01 | -3.47 | Upgrade
|
| EBT Excluding Unusual Items | 6,911 | -1,133 | -553.44 | -831.24 | -753.14 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -19.1 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 47.71 | 52.34 | -8.84 | 2.34 | -3.57 | Upgrade
|
| Asset Writedown | - | - | -11 | -1.46 | -2.17 | Upgrade
|
| Legal Settlements | - | -3.14 | - | - | - | Upgrade
|
| Other Unusual Items | 42.34 | - | -135.59 | -122.58 | - | Upgrade
|
| Pretax Income | 7,001 | -1,083 | -708.87 | -972.04 | -758.89 | Upgrade
|
| Income Tax Expense | 546.06 | -4.62 | -5.13 | -6.43 | -3.95 | Upgrade
|
| Earnings From Continuing Operations | 6,455 | -1,079 | -703.74 | -965.61 | -754.94 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | -236.53 | -263.21 | Upgrade
|
| Net Income | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 | Upgrade
|
| Net Income to Common | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 | Upgrade
|
| Shares Outstanding (Basic) | 71 | 66 | 57 | 46 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 72 | 66 | 57 | 46 | 43 | Upgrade
|
| Shares Change (YoY) | 7.70% | 17.40% | 22.49% | 7.77% | 11.73% | Upgrade
|
| EPS (Basic) | 91.56 | -16.24 | -12.44 | -26.02 | -23.75 | Upgrade
|
| EPS (Diluted) | 90.22 | -16.24 | -12.44 | -26.02 | -23.75 | Upgrade
|
| Free Cash Flow | 6,499 | -940.87 | -436.91 | -954.02 | -1,234 | Upgrade
|
| Free Cash Flow Per Share | 90.83 | -14.16 | -7.72 | -20.65 | -28.79 | Upgrade
|
| Gross Margin | 99.99% | 87.44% | 99.07% | 100.00% | 89.89% | Upgrade
|
| Operating Margin | 75.06% | -2024.33% | -163.73% | -785.30% | -720.57% | Upgrade
|
| Profit Margin | 70.05% | -1720.87% | -205.30% | -1156.05% | -937.99% | Upgrade
|
| Free Cash Flow Margin | 70.52% | -1500.80% | -127.46% | -917.45% | -1136.94% | Upgrade
|
| EBITDA | 6,927 | -1,258 | -554.7 | -729.52 | -768.57 | Upgrade
|
| EBITDA Margin | 75.17% | - | -161.82% | - | - | Upgrade
|
| D&A For EBITDA | 9.95 | 10.58 | 6.54 | 87.08 | 13.57 | Upgrade
|
| EBIT | 6,917 | -1,269 | -561.24 | -816.6 | -782.14 | Upgrade
|
| EBIT Margin | 75.06% | - | -163.73% | - | - | Upgrade
|
| Effective Tax Rate | 7.80% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.